Literature DB >> 2908138

A new parenteral emulsion for the administration of taxol.

B D Tarr1, T G Sambandan, S H Yalkowsky.   

Abstract

Taxol (NSC-125973) is a poorly soluble plant product that exhibits excellent antimitotic properties. This study involves the development of a new formulation for taxol. The stability of taxol in a 50% triacetin emulsion as well as possible methods of intravenous administration of this dosage form was examined. A stable emulsion was found at taxol concentrations of 10 and 15 mg/ml of emulsion. The 50% triacetin emulsion showed an intravenous LD50 of 1.2 ml/kg in Swiss-Webster mice. The 10 mg/ml taxol formulation was demonstrated to be stable upon addition to 5% dextrose iv fluids provided that small packing systems were used. The taxol-triacetin emulsion can also be intravenously injected at various rates, and it may prove to be a useful formulation for taxol.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2908138     DOI: 10.1023/a:1016483406511

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  7 in total

Review 1.  Physiology and physiopathology of the reticuloendothelial system.

Authors:  T M Saba
Journal:  Arch Intern Med       Date:  1970-12

Review 2.  Taxol: an antimitotic agent with a new mechanism of action.

Authors:  J J Manfredi; S B Horwitz
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

3.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

Authors:  M C Wani; H L Taylor; M E Wall; P Coggon; A T McPhail
Journal:  J Am Chem Soc       Date:  1971-05-05       Impact factor: 15.419

4.  In vitro method for detecting precipitation of parenteral formulations after injection.

Authors:  S H Yalkowsky; S C Valvani; B W Johnson
Journal:  J Pharm Sci       Date:  1983-09       Impact factor: 3.534

5.  Chronic liposome administration in mice: effects on reticuloendothelial function and tissue distribution.

Authors:  T M Allen; L Murray; S MacKeigan; M Shah
Journal:  J Pharmacol Exp Ther       Date:  1984-04       Impact factor: 4.030

6.  Complement-mediated reactions to diazepam with Cremophor as solvent (Stesolid MR).

Authors:  M S Hüttel; A Schou Olesen; E Stoffersen
Journal:  Br J Anaesth       Date:  1980-01       Impact factor: 9.166

7.  Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity.

Authors:  W Lorenz; A Schmal; H Schult; S Lang; C Ohmann; D Weber; B Kapp; L Lüben; A Doenicke
Journal:  Agents Actions       Date:  1982-04
  7 in total
  14 in total

1.  Development of paclitaxel-TyroSpheres for topical skin treatment.

Authors:  Brian E Kilfoyle; Larisa Sheihet; Zheng Zhang; Marissa Laohoo; Joachim Kohn; Bozena B Michniak-Kohn
Journal:  J Control Release       Date:  2012-06-23       Impact factor: 9.776

2.  Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization.

Authors:  Sang Cheon Lee; Kang Moo Huh; Jaehwi Lee; Yong Woo Cho; Raymond E Galinsky; Kinam Park
Journal:  Biomacromolecules       Date:  2007-01       Impact factor: 6.988

3.  Development of novel chitosan derivatives as micellar carriers of taxol.

Authors:  A Miwa; A Ishibe; M Nakano; T Yamahira; S Itai; S Jinno; H Kawahara
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

4.  A differential scanning calorimetry study of phosphocholines mixed with paclitaxel and its bromoacylated taxanes.

Authors:  S Ali; S Minchey; A Janoff; E Mayhew
Journal:  Biophys J       Date:  2000-01       Impact factor: 4.033

Review 5.  Progress in the development of alternative pharmaceutical formulations of taxanes.

Authors:  B Nuijen; M Bouma; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

6.  Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel.

Authors:  P P Constantinides; K J Lambert; A K Tustian; B Schneider; S Lalji; W Ma; B Wentzel; D Kessler; D Worah; S C Quay
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

7.  Formulation optimization of paclitaxel carried by PEGylated emulsions based on artificial neural network.

Authors:  Tianyuan Fan; Kozo Takayama; Yoshiyuki Hattori; Yoshie Maitani
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

8.  A method for the early evaluation of the effects of storage and additives on the stability of parenteral fat emulsions.

Authors:  J Li; K D Caldwell; B D Anderson
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

9.  The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: synthesis, self-assembled property, drug release, and in vitro efficiency.

Authors:  Dingcheng Xin; Ying Wang; Jiannan Xiang
Journal:  Pharm Res       Date:  2009-10-30       Impact factor: 4.200

10.  Novel taxol formulations: preparation and characterization of taxol-containing liposomes.

Authors:  A Sharma; R M Straubinger
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.